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essential in any trial of adjuvant or neoadjuvant therapy.
However, a survey of surgeons performing lung cancer
resections in the United Kingdom found that 45% of
these surgeons would not routinely sample macroscopi-
cally normal mediastinal lymph nodes at thoracotomy,
with only 23% routinely excising all mediastinal lymph
nodes.1 Furthermore, enthusiasm for video-assisted
techniques has led some surgeons to abandon systematic
nodal dissection in their normal practice, with a recent
suggestion that thoracoscopic resection without medi-
astinal node dissection might be adequate for some
small, peripheral tumors.2
In the Royal Brompton Hospital we routinely excise
and submit separately for histologic examination all
accessible ipsilateral mediastinal nodes in all patients
undergoing resection of lung cancer. If pneumonectomy
is not required for resection of the primary tumor, the
appropriate interlobar and lobar nodes are examined in
a similar fashion to objectively determine the appropri-
ate level of resection. We reviewed our findings with
S ystematic nodal dissection is an essential componentof the intrathoracic staging of disease in patients
undergoing thoracotomy for lung cancer. It allows con-
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resection is balanced by the probability of cure, and it is
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this policy to assess the information provided through
its routine application, even when lymph node metas-
tases are not suspected.
Methods
Patients. The cases of patients undergoing thoracotomy for
resection of non–small cell lung cancer by a single consultant
surgeon during the 5-year period starting in 1990 were found
in the thoracic surgery database. During this time any patient
who had been determined to have N2 disease before thoraco-
tomy was not operated on, and neither neoadjuvant nor post-
operative adjuvant therapy was used. After those undergoing
resection of recurrent lung cancer or primary tracheal malig-
nancies were excluded, 240 patients remained. Mediastinal
dissection was contraindicated because of poor medical con-
dition and limited resection options in 3 cases, because of pre-
vious mediastinal node dissection for a previous primary lung
cancer in 1 case, and because of previous mediastinal irradia-
tion in another case. In 8 patients (3%) resection of the tumor
was not undertaken after full assessment at thoracotomy, and
5 of these patients had N2 disease. In 3 of these patients sys-
tematic nodal dissection permitted the decision not to proceed
with resection; 2 had multilevel N2 disease and 1 had limited
N2 disease but with a risk of pneumonectomy that was con-
sidered to outweigh the chance of cure. The remaining patients
underwent exploratory thoracotomy because of mediastinal
invasion (n = 2), parietal pleural dissemination (n = 2), or pre-
viously undisclosed bilateral bronchoalveolar carcinoma in
the presence of a resectable squamous carcinoma (n = l).
There were thus 227 patients who underwent pulmonary
resection with systematic nodal dissection, and analysis was
restricted to this group because accurate assessment of tumor
size and status of N1 nodes would be unavailable for those
undergoing exploratory thoracotomy without resection. The
mean age (± SD) was 63.2 ± 10.1 years (range 35-87 years),
and 175 (77%) were male. Pneumonectomy was performed in
71 (31%), lobectomy (including 14 bilobectomies) was per-
formed in 138 (61%), and segmentectomy was performed in
14 (6%). A nonanatomic wedge resection was performed in 1
patient whose poor respiratory reserve precluded a more radi-
cal operation. Resections were extended to the chest wall or
mediastinum in 13 patients (6%), and bronchoplastic proce-
dures were performed in 11 patients (5%).
Clinical staging. All patients had disease clinically staged as
cT1-3 N0-1. Initial assessment was conducted by history,
examination, blood tests, and chest radiography. All patients
underwent computed tomographic scan of the chest, abdomen,
and brain. Isotope bone scans were performed in those with
recent weight loss, anemia, bone pain, or elevated alkaline
phosphatase or calcium levels. Cervical mediastinoscopy (sup-
plemented by left anterior mediastinotomy if the tumor was in
the left upper lobe) was selectively performed if the computed
tomographic findings suggested invasion of the superior medi-
astinum or enlarged nodes (>1.5 cm short axis) within reach of
the mediastinoscope. Preoperative mediastinal exploration had
been carried out in 75 (33%) of the 227 patients who under-
went pulmonary resection and systematic nodal dissection and
in 5 (62%) of the 8 patients who underwent exploratory thora-
cotomy. The numbers of lymph nodal stations sampled by
mediastinoscopy ranged from 0 to 5; the median was 3.
Intrathoracic staging. Our standard approach was to per-
form a posterolateral thoracotomy and assess the primary
tumor. Histologic confirmation of the diagnosis, if not already
available, was obtained by frozen-section analysis and the T
stage was established. If the primary tumor was resectable
(T1-3), the dissection of the mediastinal nodes was com-
menced before pulmonary resection. All nodes were stored on
a piece of sterile card, labeled according to the Naruke map,3
and examined by the surgeon when the dissection was com-
pleted. Basic oncologic principles were adhered to, with the
dissection continued along anatomic planes and crushing or
transection of lymph nodes avoided. On the right side, stations
10, 4, 3, and 2 were removed and then the hilum was dissect-
ed from posterior to inferior, removing stations 7, 8, and 9.
The dissection was continued anteriorly, mobilizing the supe-
rior pulmonary vein and main pulmonary artery. On the left
side, the dissection was commenced at the aortic arch by
locating the vagus nerve and its recurrent laryngeal branch and
excising stations 5, 6, and 4; it then proceeded around the
hilum as on the right side. When this was completed the sur-
geon was able to confirm that resection of the primary tumor
by pneumonectomy was possible. Each lymph nodal station
was serially sectioned in turn, with examination for the macro-
scopic appearance of metastases. Histologic confirmation of
macroscopically involved nodes was obtained by frozen-sec-
tion analysis if necessary. This allowed the surgeon to assess
the possibility and advisability of complete resection of all
intrathoracic tumor. If the primary tumor would permit a less-
er resection by lobectomy or segmentectomy, the appropriate
interlobar and lobar nodes were examined in a similar fashion
to objectively determine the appropriate level of resection.
Statistical methods. Data on tumor size, N stage, histo-
logic type and grade, and bronchial origin were obtained
from the final pathology report. T stage and lobar origin were
taken from the surgeon’s operating notes and cross-refer-
enced with the pathology report. Univariate analysis was per-
formed, with the dependent variables being incidence of
lymph node metastases (N1 + N2 versus N0), incidence of
mediastinal node metastases (N2 versus N1), and presence of
skip metastases in the mediastinal nodes (skip N2 versus
metastases in both N1 and N2 nodes).
Contingency table data were examined for associations and
row-column homogeneity by means of 2-sided c 2 tests, with
the trend test for proportions performed as described else-
where.4 Continuous variables were assessed with the 2-sided
Student t test. Multivariate analyses were based on logistic
regression models fitted by stepwise backward progression
(P < .1) and also by stepwise forward progression (P < .05).
The dependent variable was incidence of lymph node metas-
tases (N1 and N2 versus N0). The independent variables were
sex, age, whether a previous mediastinoscopy had been per-
formed, the number of nodes sampled during any previous
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mediastinoscopy, the number of nodes sampled during the
thoracotomy, tumor size, histologic type, histologic grade, T
stage, lobe of origin, and whether the tumor was peripheral or
central. Analysis was performed with SPSS Version 6.1
(SPSS Inc, Chicago, Ill).
Results
The median number of nodal stations, including N1
and N2, examined and submitted separately for histo-
logic assessment was 7 per patient (range 3-13). The
mean (± SD) number of N1 nodal stations submitted
separately increased from 1.4 ± 0.9 in the first year of
the study to 2.7 ± 1.3 in the last (P < .0001). The mean
number of N2 nodal stations excised separately was 4.9
± 1.2, and there was no significant change in this during
the study period. Histologic confirmation of the sur-
geon’s findings by frozen-section analysis was obtained
for N1 nodes in 42 cases (19%), N2 nodes in 54 cases
(24%), and the primary tumor in 125 cases (55%).
Lymph node metastases. Table I shows the patient
and primary tumor details for each surgical-pathologic
lymph node stage. Univariate analysis showed that the
following factors were significantly associated with
node-positive tumors (N1 and N2): younger age (P =
.005), previous mediastinoscopy (P = .004), larger tumor
diameter (P = .005), increasing T stage (P = .01), left
lower lobe origin (P = .03), and central location of tumor
(P = .0005). There were no significant differences in
these factors between patients who had mediastinal node
metastases and those who had N1 metastases. There was
a significant trend toward increasing incidence of nodal
metastases (N1 and N2) as the T stage increased from T1
to T3 (P = .01) and as the tumor became more central,
with the incidences associated with peripheral tumors
and those arising from segmental, lobar, and main
bronchi being 27%, 42%, 68%, and 73%, respectively (P
< .0001). There was no significant association between
histologic type or grade of primary tumor and presence
of lymph node metastases. Multivariate analysis showed
that younger age, increasing tumor size, left lower lobe
origin, and bronchial origin (no bronchial attachment
versus segmental versus lobar versus main) were signif-
Table I. Patient and primary tumor details in 227 patients undergoing pulmonary resection and systematic nodal
dissection
pN0 (n = 136) pN1 (n = 50) pN2 (n = 41)
Value SD or %* Value SD or %* Value SD or %* Total (n = 227)
Mean age (y) 64.8 9.9 61.4 10 60.5 10 63.3
Sex
Male 102 58% 40 23% 33 19% 175
Female 34 65% 10 19% 8 15% 52
Previous mediastinoscopy?
No 100 66% 31 21% 20 13% 151
Yes 36 47% 19 25% 21 28% 76
Mean tumor diameter (cm) 36.2 19.4 43.9 25 47.1 28.4 39.9
Cellular classification
Squamous cell 62 57% 25 23% 22 20% 109
Adenocarcinoma 58 67% 17 20% 12 14% 87
Large cell 15 56% 6 22% 6 22% 27
Adenosquamous 1 25% 2 50% 1 25% 4
T stage
T1 61 71% 16 19% 9 10% 86
T2 66 54% 27 22% 29 24% 122
T3 8 47% 7 41% 2 12% 17
T4 1 50% 0 0% 1 50% 2
Lobar origin
Right upper 44 63% 15 21% 11 16% 70
Right middle 10 77% 1 8% 2 15% 13
Right lower 25 66% 8 21% 8 13% 38
Left upper 51 58% 19 22% 18 20% 88
Left lower 6 33% 7 39% 5 28% 18
Location of primary†
Peripheral 70 73% 14 15% 12 12% 96
Central 62 49% 36 28% 29 23% 127
*SD for mean values, percentage of total (final column) for numbers of patients.
†In 4 patients the location of the primary could not be classified.
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icant independent variables for prediction of lymph node
metastases (Table II). Interaction terms between these
variables were all significant, except that between age
and bronchial origin, confirming that the relationships
among these variables and the incidence of lymph node
metastases are complex.
Small, peripheral tumors. Because it has been sug-
gested that thoracoscopic wedge resection without
mediastinal node dissection may be adequate for some
small, peripheral tumors,2 we examined the findings in
this subgroup of patients (Table III). Sixty percent of
peripheral tumors 2 cm or smaller in diameter were
adenocarcinomas, compared with 35% of more central
or larger tumors (P = .03). Twenty-four percent of
peripheral tumors 2 cm or smaller in diameter had
lymph node metastases, with the incidence being 26%
if 3 cm was used as the cutoff point.
Skip metastases. In 14 patients metastases were
detected in mediastinal nodes with documented ab-
sence in N1 nodes. Table IV shows comparisons
between the primary tumors in patients with these “skip
metastases” and those with metastases in both N1 and
N2 nodes. Skip metastases were more common with
peripheral (P = .04) and right-sided tumors (P = .01).
The sites of mediastinal lymph node metastases in
patients with skip metastases and those with metastases
in both N1 and N2 nodes are shown in Table V.
Discussion
Mediastinal node dissection has become accepted as
an integral component of the intrathoracic staging of
disease in patients undergoing resection of non–small
cell lung cancer5 because the presence of metastases in
mediastinal lymph nodes has been shown to be the most
important indicator of a low chance of survival after
resection,6,7 and all currently available modalities for
assessing mediastinal lymph node status before the
operation have inadequate sensitivities for their detec-
tion.8,9 The accuracy of this clinical evaluation of the
lymph nodes by the surgeon at the time of the operation,
supplemented by histologic confirmation by frozen-sec-
tion analysis where appropriate, has already been
demonstrated.9,10 Much confusion has been generated
by the different terms, such as radical lymphadenecto-
my or lymph node sampling, used to describe lymph
node dissection at thoracotomy. At an international
workshop held at the National Heart and Lung Institute
in London in October 1996 and supported by the
International Association for the Study of Lung Cancer,
a recommendation was made that the term systematic
nodal dissection be used to describe the procedure that
is most commonly carried out, a staging procedure con-
sisting of dissection and examination of mediastinal,
hilar, and lobar lymph nodes in a systematic fashion.11
In this series only 2% of patients had systematic
nodal dissection omitted, in all cases because of specif-
ic contraindications. In only 3% was exploratory thora-
cotomy only performed, and this both compares well
with the 10 to 15%12,13 rate in recent reports and
reflects the thorough approach to preoperative staging
in our unit, as previously documented.14 Because
neoadjuvant chemotherapy was not routinely used dur-
ing the period of this study, patients with cN2 disease
confirmed at mediastinoscopy were treated with non-
operative therapy. At thoracotomy, N2 disease was dis-
closed in 46 patients overall (20%), including 41 of the
227 patients undergoing pulmonary resection (18%)
and 5 of those undergoing exploratory thoracotomy
(62.5%). The incidence of pN2 disease was higher
among those who had undergone previous medi-
astinoscopy, reflecting both the policy of its selective
use and its lack of 100% sensitivity for discriminating
patients with N2 disease.
There was a significant trend toward increasing inci-
dence of lymph node metastases (N1 and N2) among
Table II. Results of multivariate analysis: Significant
findings
Variable b SE P
Age (y) –.037 0.015 .01
Tumor diameter (mm) .016 0.006 .01
Lobe of origin .12
Upper versus middle .331 0.247 .18
Middle versus lower –.829 0.404 .04
Bronchial origin .627 0.176 <.001
Constant –.135 1.016 .9
Significant findings on multivariate analysis (forward and backward stepwise
analysis gave identical results). b , Logistic regression coefficient.




Squamous cell 8 0 1†
Adenocarcinoma 11 3 1†
Large cell 0 0 0
Adenosquamous 0 1 0
≤3 cm
Squamous cell 12 0 1†
Adenocarcinoma 11 3 1†
Large cell 3 1 2
Adenosquamous 0 1 0
*Small, peripheral tumors (excluding those with a bronchial connection); that
is, those that would be technically resectable by thoracoscopic wedge.
†Skip metastasis.
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patients with primary tumors that were more central,
and multivariate analysis showed that younger age,
increasing tumor size, left lower lobe origin, and
bronchial origin were significant independent variables
predicting lymph node metastasis. The effect of age
probably represents a bias in patient selection, because
elderly patients were less likely than young ones to be
offered surgical treatment if the initial investigations
showed that the tumor was probably of advanced stage.
Interaction terms between these variables were all sig-
nificant, except that between age and bronchial origin,
confirming that there is a complex relationship among
these variables. There were no significant predictors of
stage N2 versus stage N1.
There has been recent debate regarding the need for
mediastinal node dissection in patients with small,
peripheral tumors, with a recent report from the
National Cancer Centre in Tokyo documenting medi-
astinal lymph node metastases associated with 6.2% of
peripheral, squamous tumors 2 cm in diameter or
smaller and with 2.3% of those 3 cm in diameter or
smaller with hilar nodes free of tumor.2 The authors
suggested that mediastinal lymph node dissection
might be omitted in these patients. We found these 2
subsets to have pN2 disease in 11% and 8% of cases,
respectively, and we therefore believe that mediastinal
dissection cannot be omitted in the case of small,
peripheral tumors. An additional argument against this
selective policy is that it depends on accurate cellular
classification of the primary tumor, which is unlikely to
be known before the operation for these small, bron-
choscopically negative tumors and is not reliably deter-
mined by frozen-section analysis. For all patients with
peripheral tumors 2 cm in diameter or smaller, the inci-
dence of N2 disease was 8%, similar to the range of 8%
to 12% previously reported.2,15-17
Skip metastases occurred in 34% of patients with N2
disease, similar to the recently reported range of 29%
to 33%.18-20 Right-sided primary tumors were signifi-
cantly more likely to be associated with skip metas-
tases (P = .01), and this has previously been seen in
some studies20 but not in others.18,19 The reasons for
this association are unclear but do not appear to include
sampling error, because the mean number of N1 levels
sampled was greater on the right side (data not shown).
Although the incidences of skip metastases were simi-
lar for peripheral and central tumors at 7% and 5%,
respectively, there was an increased incidence of N2
metastases associated with N1 metastases for central
tumors (17%) compared with peripheral tumors (5%, P
= .01). Few other studies have addressed this issue, but
those that have done so have had similar findings.19
This decreased propensity of central tumors toward
skip metastases may be explained by the findings of
direct lymphatic pathways to mediastinal nodes by
injection of the peripheral subpleural lymphatics in
cadavers.21 The significant incidence of skip metas-
tases from peripheral tumors reinforces the need for a
full lymph node dissection in these patients.
The sites of mediastinal metastases found essentially
confirm the work of previous investigators in this
field.2,3,16 Metastases to subcarinal nodes occurred with
primary tumors in all lobes, which would support the
contention that these nodes should always be excised
regardless of the site of the primary tumor.22
There has been some concern regarding possible
adverse effects of mediastinal node dissection, with a
Table IV. Skip N2 cases versus N2 cases without skip
Skip (n = 14) No skip* (n = 27)
No. %† No. %†
Site of primary
Peripheral 7 58 5 42
Central 7 24 22 76
Cellular classification
Adenocarcinoma 5 42 7 58
Squamous cell 6 27 16 73
Large cell 3 3
Adenosquamous 1
Side of primary
Right 10 56 8 44
Left 4 17 19 83
Lobar origin
Upper 11 37 19 63
Middle 0 2 7
Lower 3 33 6 67
*Metastases in both N1 and N2 nodes.
†Percentage of row totals (skip + no skip).
Table V. Sites of mediastinal lymph node metastases
(N2 stations)
Upper Aortic Inferior 
Site of primary (2-4) (5-6) (7-9) Total
N2, no skip*
RUL 5 1 5
RML 1 2 2
RLL 1 1
LUL 8 10 4 14
LLL 2 3 5 5
Skip N2
RUL 6 1 7
RLL 1 3 3
LUL 2 3 4
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL,
left upper lobe; LLL, left lower lobe.
*Metastases in both N1 and N2 nodes.
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suggestion that it may predispose the patient toward the
development of acute respiratory distress syndrome. The
overall incidences according to strict diagnostic criteria23
of acute respiratory distress syndrome and acute lung
injury among the patients undergoing pneumonectomy
and lobectomy were 8% and 3%, respectively. Precise
figures for the development of these conditions after
lung resection without mediastinal dissection are not
available for comparison, although the higher incidence
after pneumonectomy than lobectomy with an identical
mediastinal dissection seen in this and other studies24
suggests that the volume of lung resected, rather than the
mediastinal dissection, is the main risk factor. Another
concern raised has been a possible adverse effect on the
immunologic response to dissemination of cancer cells,
with a report of lower survival among patients with T1
N0 M0 tumors who underwent complete ipsilateral
mediastinal node dissection than among those who
underwent hilar node dissection and mediastinal node
sampling.25 Because patients in that study were not ran-
domly assigned to treatment groups, however, there was
a potential for bias in the selection of patients for medi-
astinal dissection. In addition, the number of nodal sta-
tions “sampled” was not reported. The true potential of
mediastinal node dissection to predispose the patient
toward these 2 possible adverse effects can only ever be
determined by a randomized, controlled trial.
We found that the routine application of systematic
nodal dissection to patients with disease clinically staged
as cN0-1 found significant incidence of pN2 in every sub-
set analyzed. We therefore believe that systematic nodal
dissection must be routinely employed at thoracotomy if
the intrathoracic stage of disease in patients with
non–small cell lung cancer is to be accurately determined.
We thank Dr Gordon W. Cran, PhD, for statistical advice.
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